Pfizer PFE will report its third-quarter 2024 earnings on Oct. 29, before market open. The Zacks Consensus Estimate for sales ...

PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.

Stanley Laman Group Ltd. cut its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3.2% in the 3rd quarter, Holdings ...

Buy Pfizer. Some investors might think Pfizer (NYSE: PFE) is a healthcare stock to avoid rather than buy hand over fist. That ...

Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.

Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. Receive News & Ratings for Pfizer ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

Even with an 87% drop in Comirnaty sales, Pfizer achieved 14% operational growth in the second quarter, driven by its diversified portfolio, including key products like Eliquis and new oncology drugs.

This product group includes Comirnaty, Pfizer's mRNA COVID-19 vaccines, which saw a revenue drop-off of $195M (-87% Y/Y). The weakness in primary care products, however, has been offset by growth ...

But the court ruled another similar patent was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022.